Stock comparison
Halozyme Therapeutics
Pfizer
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
PFE
Pfizer
Market cap
$147.62B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | PFE | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 55C | HALO |
| Benjamin Graham | 83A | 53C | HALO |
| Philip Fisher | 65B | 47D | HALO |
| Peter Lynch | 53D | 22F | HALO |
| Joel Greenblatt | 40D | 31F | HALO |
| Charlie Munger | 80C | 58D | HALO |
| Terry Smith | 84A | 54D | HALO |
Side-by-side metrics
| Metric | HALO | PFE |
|---|---|---|
| Market cap | $8.1B | $147.62B |
| P/E (TTM) | 24.0x | 19.2x |
| EV/EBIT | 10.2x | 13.4x |
| ROIC (TTM) | 23.65% | 7.97% |
| Gross margin | 81.24% | 69.35% |
| Net margin | 23.13% | 11.83% |
| Revenue CAGR 5y | 33.23% | -6.33% |
| EPS CAGR 5y | -1.98% | -23.42% |
| Debt / Equity | 1.0x | 0.7x |
| Dividend yield | 0.0% | 6.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -6.33%+119%
- EPS CAGR 5y-1.98%vs -23.42%+92%
- ROIC (TTM)23.65%vs 7.97%+66%
- Net margin23.13%vs 11.83%+49%
PFE leads on
- Dividend yield6.79%vs 0.0%+100%
- Market cap$147.62Bvs $8.1B+95%
- Debt / Equity0.7xvs 1.0x+25%
- P/E (TTM)19.2xvs 24.0x+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.